Avoiding Missteps in the Diagnosis and Management of Hypophosphatasia

San Diego, CA US

Friday, March 6, 2015; 6:30 – 9:30 PM PST
Hilton San Diego Bayfront Hotel, Sapphire Ballroom B

This course is a live CME-certified ancillary symposium presented at ENDO 2015, the Endocrine Society's 97th Annual Meeting and Expo, held in San Deigo, California, March 5–8, 2015. ENDO 2015 ancillary symposia are developed through the Endocrine Society’s Special Programs Committee (SPC). There is no cost to attend, and all ENDO 2015 attendees are welcome; however, seating is limited and advance registration is recommended. You must be registered for ENDO 2015 to attend an ENDO 2015 ancillary  symposium.

This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc. 


Welcome and Introduction
Program Director: Jill H. Simmons, MD – Vanderbilt University

Clinical Manifestations of HPP: Genetics and Physiology
Linda DiMeglio, MD, MPH – Indiana University 

Diagnosing HPP: Genetic, Chemical, Biochemical, and Radiologic Testing
Peter J. Tebben, MD – Mayo Clinic

HPP Management
Eric T. Rush, MD – University of Nebraska

Clinical Trials and Emerging Therapies in HPP Management
Michael P. Whyte, MD – Shriners Hospital for Children 

Expert Summaries: Future Directions and Unknown Questions

Target Audience

This program should be of substantial interest to endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals treating metabolic bone diseases.

Learning Objectives

Upon completion of this educational activity, participants will be better able to:

  • Discuss the genetic underpinnings and pathophysiology of  hypophosphatasia
  • Recognize skeletal and non-skeletal sequelae of hypophosphatasia
  • Evaluate chemical, biochemical, and radiological tests in the diagnosis of hypophosphatasia
  • Describe the mechanism and use of emerging therapies in the management of hypophosphatasia
  • Summarize current clinical studies on the safety and efficacy of fusion protein treatment in hypophosphatasia


Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Topic Area: 
Bone and Calciotropic Hormones
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Level 5 (Performance (Does))
Activity summary
Available credit: 
  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation
Course opens: 
Course expires: 
Hilton San Diego Bayfront
1 Park Boulevard
Sapphire Ballroom B
San Diego, CA 92101
United States

Jill H. Simmons, MD – Program Director
Associate Professor, Pediatrics
Monroe Carell Jr. Children’s Hospital
Vanderbilt University School of Medicine
Nashville, Tennessee

Linda A. DiMeglio, MD, MPH
Professor, Pediatric Endocrinology/Diabetology
Director, Type 1 Diabetes Research Team
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana

Peter J. Tebben, MD
Mayo Clinic
Departments of Internal Medicine and Pediatrics
Division of Endocrinology
Rochester, Minnesota 

Eric T. Rush, MD
Clinical Geneticist
Munroe-Meyer Institute for Genetics and Rehabilitation
Assistant Professor of Pediatrics and Internal Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Michael P. Whyte, MD
Medical-Scientific Director
Center for Metabolic Bone Disease and Molecular Research
Shriners Hospital for Children
St.Louis, Missouri


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

Eric T. Rush, MD: Advisory Board Member, Alexion
Peter J. Tebben, MD: Advisory Board Member, Alexion
Michael P. Whyte, MD: Principal Investigator, Alexion

The following faculty reported no relevant financial relationships: Jill H. Simmons, MD

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships: Larry Fox, MD

The following SPC Committee members reported relevant financial relationships:
Sarah Berga, MD: Advisory Board, Agile Therapeutics, Noven Pharmaceuticals, Inc., Watson Pharmaceuticals, Teva Pharmaceuticals Industries, Shionogi, Inc.; Consultant, AHC Media, LLC, Shionogi, Inc.
Paresh Dandona, MD, PhD, FRCP: Consultant and Speaker, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Novo Nordisk
Henry Fein, MD: Investigator, Corcept Therapeutics
Irl Hirsch, MD: Consultant, Abbott Laboratories, Johnson & Johnson, Roche Diagnostics, Valeritas; Investigator, Sanofi
Anton Luger, MD: Advisory Board, Investigator and Speaker, Novo Nordisk; Advisory Board and Speaker, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Ipsen, Merck, Merck, Sharp & Dome, Novartis, Pfizer, Reckitt Benkiser, Takeda; Investigator, Roche
Andrea L. Utz, MD, PhD: Advisory Board, Corcept, Ipsen

The following SPC members reported no relevant financial relationships: Jeffrey Boord, MD, MPH; Connie Newman, MD

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 2.50 AMA PRA Category 1 Credits
  • 2.50 CME Certificate of Participation